Reboxetine (brand names: Edronax (AU, IE, IL, NZ, ZA, UK), Prolift (AR,† BR, CL, VE†)) is a drug of the norepinephrine reuptake inhibitor class, marketed as an antidepressant by Pfizer for use in the treatment of unipolar depression, although it has also been used off-label for panic disorder and ADHD. It is approved for use in many countries worldwide, but has not been approved for use in the United States. Although its efficacy as an antidepressant has been challenged in multiple published reports, its popularity has continued to increase.

CAS：71620-89-8
中文别名：(2R)-2-[(R)-(2-乙氧基苯氧基)苯甲基]吗啉甲磺酸盐;
英文别名：(+/-)-(2S,3S)-iodoreboxetine;1-bromo-2,3-epoxy-3-phenylpropane;3-Bromomethyl-2-phenyloxirane;trans-Cinnamyl bromide epoxide;Oxirane,2-(bromomethyl)-3-phenyl;2-bromomethyl-3-phenyloxirane;trans-3-bromo-1-phenyl-1,2-epoxypropane;(+/-)-(2S,3R)-2-(bromomethyl)-3-phenyloxirane;
分子式：C19H23NO3
分子量：313.391
精确质量：313.168
Psa：39.72
Logp：3.5226

MDL号：MFCD28142770

外观与性状：白色固体
密度：1.113 g/cm3
沸点：443.7ºC at 760 mmHg
熔点：141-143ºC
闪点：188.2ºC
储存条件：Desiccate at +4ºC